02453 CONCORD HC GP
- 34.150
- -0.450-1.30%
CONCORD HC GP News
Concord Healthcare Updates Partnership, Disposal of Interests Terms
Concord Healthcare Group (HKG:2453) logged additional information regarding previously formed partnerships, and the deemed disposals of interests in three of its subsidiaries, according to a filing wi
Yoshikazu US and China (02453) proposed implementing full circulation of H shares
According to the Zhitong Finance App, the US and China Jiahe (02453) announced that the company submitted an application to the China Securities Regulatory Commission on April 30, 2024 to convert some domestic shares with a face value of RMB 1.00 per share of companies issued abroad to H shares with a face value of RMB 1.00 per share of companies listed on the main board of the Stock Exchange. After obtaining all relevant approvals (including filing and/or approval with the China Securities Regulatory Commission and the Stock Exchange) and complying with all applicable laws, regulations and rules, these domestic shares will be converted to H shares, and the company will apply for listing and trading of these H shares on the main board of the Stock Exchange. On the date of this announcement
Yoshikazu America and China (02453.HK) set up three partnerships with independent third parties to seek long-term strategic development opportunities
Gelonghui, April 26, 丨 US and China Jiahe (02453.HK) announced that in order to promote the company's strategic development and business operation needs, the company and an independent third party set up three partnerships to manage minority shares in the three subsidiaries (i.e. Shanghai Hospital, Shanghai Outpatient Department and Ningbo Jiahe) acquired by the independent third party as a general partner to seek strategic opportunities in line with the company's long-term development. The relevant details are as follows: On April 7, 2024, April 22, 2024, and April 7, 2024, the company and Lingbou Private Equity (independent third party) were established, respectively Joined the partnership Jiaxue Health,
美中嘉和：2023年年報
Changes in Hong Kong stocks | US-China Jiahe (02453) rose more than 17% in the afternoon to hit a new high of listing, annual revenue increased 14.1% year-on-year to $539 million
The Zhitong Finance App learned that the US and China Jiahe (02453) rose more than 17% in the afternoon to a high of HK$27.05, a record high. As of press release, it rose 13.7% to HK$26.15, with a turnover of HK$2,410,500. According to the news, the US and China Jiahe previously announced annual results, with revenue of 539 million yuan, up 14.1% year on year; the Group's hospital business revenue increased 46.5% year over year to 320 million yuan, mainly due to increased brand awareness and continued growth in medical demand. According to reports, medical institutions under the Group have achieved remarkable results in various fields. especially in tumors
Yoshikazu, the US and China (02453) announced 2023 annual results. Revenue reached 539 million yuan, a year-on-year increase of 14.1%. Radiation therapy and surgery went hand in hand
Yoshikazu America and China (02453) announced results for the year ended December 31, 2023, with revenue of 539 million yuan (...
CONCORD HC GP: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | US-China Jiahe (02453) rose more than 10%. Institutions expect future demand for cancer treatment will also increase, and private oncology medical institutions will benefit
The US-China Yoshiwa (02453) rose by more than 10% and rose 10.66% at press time to HK$23.35, with a turnover of HK$1.74 million.
Yoshikazu America and China (02453.HK) plans to hold a board meeting on March 27 to consider and approve the full year results
Yoshikazu the US and China (02453.HK) announced that the board meeting will be held on March 27, 2024 (Wednesday) to consider and approve the Group's annual results and announcements for the year ended 31 December 2023, and consider recommending payment of a final dividend (if any).
CONCORD HC GP: DATE OF BOARD MEETING
US and China Jiahe plan to guarantee the financing of subsidiaries
The US and China Yoshiwa (02453) announced that in view of the Group's business development and operation, the company plans to provide new financing guarantees to its subsidiaries for their respective financing needs. The total amount is estimated not to exceed RMB 2.7 billion. The guarantee amount is valid for 12 months from the date the company's shareholders approve the resolution at the Extraordinary General Meeting of Shareholders, in accordance with the business development plan and subject to the approval conditions, and can be transferred within the aforementioned period of validity. Therefore, the Company will submit a special resolution at the Extraordinary General Meeting of Shareholders for shareholders' consideration and appropriate approval of the Company's provision of guarantees and the authorization of the Board of Directors and/or its authorized representatives for full discretionary review
Yoshikazu America and China (02453) intends to guarantee the financing of subsidiaries
The US and China Yoshiwa (02453) announced that in view of the Group's business development and operation, the company plans to provide new financing guarantees to its subsidiaries for their respective financing needs. The total amount is estimated not to exceed RMB 2.7 billion.
Concord Healthcare Group Down 24% in Hong Kong Trading Debut
Concord Healthcare Group Down 24% in Hong Kong Trading Debut
US-China Jiahe (2453.HK), one of the largest private oncology medical service providers in China: starting a stock offering
Recently, news came from the capital market that China Jiahe Medical Technology Development Group Co., Ltd. (hereinafter referred to as US-China Jiahe), a Chinese private medical institution focusing on oncology medical solutions, officially opened a stock offering on December 29. According to the prospectus data, the prospectus price range for US and China Jiahe is HK$14.10 to HK$16.40 per share, and the first-hand entry fee is HK$3,313.08. CICC and Haitong International are co-sponsors of the company. As one of the few private medical institutions in China that also has advanced cancer diagnosis and treatment technology research and application capabilities, and has multiple proton therapy cabins,
Analysis
Price Target
No Data
